Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10548-10562

  Ip, Laura R H ^a   Poulogiannis, George ^b   Viciano, Felipe Cia ^a,c   Sasaki, Junko ^d   Kofuji, Satoshi ^d   Spanswick, Victoria J ^a   Hochhauser, Daniel ^a   Hartley, John A ^a   Sasaki, Takehiko ^d   Gewinner, Christina A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA damage repair; Inositol polyphosphate 4 phosphatase type II; INPP4B; PARP inhibition

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; HISTONE H2AX; INOSITOL POLYPHOSPHATE 4 PHOSPHATASE TYPE II; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RAD51 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; ATM PROTEIN, HUMAN; ATR PROTEIN, HUMAN; BRCA1 PROTEIN, HUMAN; PHOSPHATASE; PHOSPHATIDYLINOSITOL-3,4-BISPHOSPHATE 4-PHOSPHATASE; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; COMET ASSAY; COMPLEX FORMATION; CONTROLLED STUDY; DNA REPAIR; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN DEPLETION; PROTEIN STABILITY; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; DEFICIENCY; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; NONOBESE DIABETIC MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; SCID MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BRCA1 PROTEIN; BREAST NEOPLASMS; DNA REPAIR; FEMALE; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; OVARIAN NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; TRANSCRIPTOME; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929589870     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3307     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2007; 57:43-66.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 144:646-74.
3. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 40:179-204.
4. Morandell S, Yaffe MB. Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy. Prog Mol Biol Transl Sci. 110:289-314.
5. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008; 27:5497-510.
6. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol. 1998; 10:262-7.
7. Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 1999; 9:125-8.
8. Liu L, Damen JE, Ware M, Hughes M, Krystal G. SHIP, a new player in cytokine-induced signalling. Leukemia. 1997; 11:181-4.
9. Gewinner C, Wang ZC, Richardson A, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 2009; 16:115-25.
10. Hodgson MC, Shao LJ, Frolov A, et al. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 71:572-82.
11. Fedele CG, Ooms LM, Ho M, et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A. 107:22231-6.
12. Puc J, Keniry M, Li HS, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005; 7:193-204.
13. Puc J, Parsons R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle. 2005; 4:927-9.
14. Plo I, Laulier C, Gauthier L, Lebrun F, Calvo F, Lopez BS. AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res. 2008; 68:9404-12.
15. Kim JS, Yun HS, Um HD, et al. Identification of inositol polyphosphate 4-phosphatase type II as a novel tumor resistance biomarker in human laryngeal cancer HEp-2 cells. Cancer Biol Ther. 13:1307-18.
16. Weigman VJ, Chao HH, Shabalin AA, et al. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 133:865-80.
17. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361:123-34.
18. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004; 6:1-6.
19. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 28:3555-61.
20. Gupta A, Yang Q, Pandita RK, et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle. 2009; 8:2198-210.
21. Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007; 128:157-70.
22. Mah LJ, Orlowski C, Ververis K, El-Osta A, Karagiannis TC. Utility of gammaH2AX as a molecular marker of DNA double-strand breaks in nuclear medicine: applications to radionuclide therapy employing auger electron-emitting isotopes. Curr Radiopharm. 4:59-67.
23. Chanoux RA, Yin B, Urtishak KA, Asare A, Bassing CH, Brown EJ. ATR, and H2AX cooperate in maintaining genome stability under replication stress. J Biol Chem. 2009; 284:5994-6003.
24. Banath JP, Klokov D, MacPhail SH, Banuelos CA, Olive PL. Residual gammaH2AX sfoci as an indication of lethal DNA lesions. BMC Cancer. 10:4.
25. Wang B, Matsuoka S, Carpenter PB, Elledge SJ. 53BP1, a mediator of the DNA damage checkpoint. Science. 2002; 298:1435-8.
26. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 12:587-98.
27. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434:917-21.
28. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003; 9:568-74.
29. Rhiem K, Wappenschmidt B, Bosse K, Koppler H, Tutt AN, Schmutzler RK. Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer. Clin Oncol. 2009; 21:448-50.
30. Ratner ES, Sartorelli AC, Lin ZP. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol. 24:564-71.
31. Sgagias MK, Wagner KU, Hamik B, et al. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle. 2004; 3:1451-6.
32. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002; 82:373-428.
33. Xu N, Lao Y, Zhang Y, Gillespie DA. Akt: a double-edged sword in cell proliferation and genome stability. J Oncol. 2012: 951724.
34. Tutt A, Robson M, Garber JE, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proofof-concept trial. Lancet. 376:235-44.
35. Audeh MW, Carmichael J, Penson RT, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 376:245-51.
36. Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2:1048-63.
37. Ibrahim YH, Garcia-Garcia C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2:1036-47.
38. Riker AI, Enkemann SA, Fodstad O, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008; 1:13.
39. Gill R. Understanding Cox's regression model. Experientia Suppl. 1982; 41:187-99.
40. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003; 100:10393-8.
41. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3:Article3.
42. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses. 1995; 45:486-90.
43. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545-50.
44. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods. 2003; 30:256-68.
45. Spandidos A, Wang X, Wang H, Seed B. PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res. 38:D792-9.
46. Katzen F. Gateway((R)) recombinational cloning: a biological operating system. Expert Opin Drug Discov. 2007; 2:571-89.
47. Harper S, Speicher DW. Purification of proteins fused to glutathione S-transferase. Methods Mol Biol. 681:259-80.
48. Spanswick VJ, Hartley JM, Hartley JA. Measurement of DNA interstrand crosslinking in individual cells using the Single Cell Gel Electrophoresis (Comet) assay. Methods Mol Biol. 613:267-82.